Roche presented detailed Phase 3 results for its oral selective estrogen receptor degrader (SERD), giredestrant, reporting significant progression‑free survival (PFS) gains in both ESR1‑mutant and non‑mutant ER‑positive, HER2‑negative breast cancer cohorts. The company described the pill as the first SERD to show benefit in patients without ESR1 mutations, potentially widening the drug’s clinical use. The evERA trial showed hazard ratios translating to 44% and 62% PFS improvements in the intention‑to‑treat and ESR1‑mutant populations, respectively. Roche argued the totality of data supports broader access and compared giredestrant favorably against injectable fulvestrant in previously treated patients. Investigators noted overall survival data remain immature and emphasized post‑hoc analyses and safety monitoring as part of regulatory discussions. The findings will shape competition between oral SERDs and existing endocrine options and influence combination strategies with targeted agents.